Category: Cancer Research

Research in Oncotarget Suggests New Cancer Treatment Options

Cancer has been one of the most pressing medical issues in human history. Since the early years of modern medicine, oncologists and medical practitioners have been fooled by the resilience of malignant cells in the human body. These cells result in a wide range of health issues, including melanoma, leukemia, and other forms of cancer. Cancer is prevalent in every society to varying degrees. Therefore, cultural traits, dietary habits, and environmental factors cannot be blamed for all cases of cancer.While many researchers aim to discover the causes of cancer, some oncologists hope to learn the mechanisms of cancer cell replication. By discovering the processes of replication, researchers can find weaknesses. These weaknesses can be exploited for treatment options. These research efforts have led to several breakthroughs in recent years. For example, oncologists have discovered how to improve chemotherapy treatments for lung cancer patients by isolating certain biomarkers. These discoveries are promising for the future of oncology, but cancer remains a deadly disease.In most cases, cancer can be treated effectively in early-stage patients. For doctors to detect early-stage cancers, patients must visit their medial practitioner for routine examinations.

Unfortunately, many people prefer to avoid these examinations. In the future, technology may improve early-detection rates.If malignant cells are not destroyed during the early stages of cancer, a patient’s probability of survival decreases. Survival rates are extremely low for patients who have malignant cells that developed into stage four cancer. Consider the example of breast cancer. During the early stages of breast cancer, the tumors can simply be removed via surgery. This is not the case for late-stage breast cancer. Malignant cells tend to spread rapidly. When this happens, tumors can develop in numerous organs across the body.In these dire cancer cases, the chances of survival are slim. This is because oncologists do not have an effective means of neutralizing the disease. Surgery remains an option, but malignant cells are difficult to remove in some organs. For many late-stage patients, chemotherapy is the only viable treatment option. Chemotherapy is considered to be a blunt treatment. Some cancers can resist chemical and radiation treatments. Chemotherapy treatments can also result in extreme side-effects. It is clear that researchers need to discover new treatment options that are effective at all stages of cancer.

Searching for an Cancer’s Achilles’ Heel

To discover an effective treatment option for serious forms of cancer, oncologists must find a weakness in the replication process of malignant cells. If doctors can halt the replication of malignant cells, they can stop the spread of cancers in patients. This kind of discovery would be groundbreaking.Many researchers refer to this kind of weakness as the Achilles’ heel of cancer. In Greek mythology, Achilles was a warrior who was nearly invincible. To his opponents, Achilles was immune to physical harm. However, Achilles lost his invincibility when his heel was struck by an arrow. Achilles’ only weakness was exploited, and he perished during the sacking of Troy.The story of Achilles is appropriate for the field of oncology. In many cases of late-stage cancer, malignant cells seem invincible. Despite numerous chemotherapy and surgery treatments, relapse often occurs in late-stage patients. Researchers hope to find the weakness that will remove the replication abilities of malignant cells. This discovery would allow doctors to use less invasive options. Furthermore, patients could expect higher rates of success. This would eventually reduce the stress associated with cancer diagnoses.

Researchers Discover a Critical Weakness

While findings have not evolved into practical treatment options, some researchers may have discovered the Achilles’ heel of cancer cells. Garth Owens, an oncology researcher, analyzed several articles published in the journal Oncotarget in 2016 and 2016. In his statements about the existence of an Achilles’ heel for cancer, Owens acknowledged that the replication process of non-coding RNA is unknown in mainstream medicine. He believes that medical professionals must understand this process to eradicate cancer.Mainstream oncology has not deciphered the secrets of cancer, but recent papers published in Oncotarget present potential weaknesses in malignant cells. These weaknesses deal with oligonucleotides.Oligonucleotides are polynucleotides that have a small number of nucleotides. These kinds of polynucleotides are short RNA or DNA molecules. Their functions are not fully understood by oncologists, oligonucleotides are important in the field of genetics.Researchers learned that oligonucleotides can be applied to non-coding mitochondrial RNA. This application curbs tumor development in numerous pre-clinical models. Researchers also learned that the application of oligonucleotides to non-coding mitochondrial RNA can prevent metastasis.This breakthrough was discovered by the Burzio research team in 2009. While analyzing the nucleus of a sperm cell, the Burzio team noticed an odd relationship between non-coding mitochondrial RNA and cancer. This relationship deals with the splicing and ligation of 16S sense and antisense RNA. In biology, sense RNA refers to a strand that is translatable into protein. Antisense RNA refers to a non-coding strand of RNA that complements mRNA.The researchers compared healthy sperm nuclei to cancerous counterparts. The Burzio research team discovered that different structures were present in the samples. In malignant cells, the stem-loop structures are altered. Due to extreme variations in the stem-loop structures, the antisense transcripts are nearly undetectable. It is important to note that the antisense transcripts are still present. The minimal presence of the antisense transcripts can be credited to a process of down-regulation.If the antisense transcripts continued to be down-regulated, the cancer cells would be forced to enter a death cycle. This cellular mechanism is akin to a self-destruction process. With this knowledge, the Burzio research team aimed to exploit this down-regulation weakness.

A New Way to Eliminate Cancer Cells

By triggering the down-regulation process in the antisense transcripts of cancer cells, the Burzio team hoped to kill malignant cells. To study the viability of a down-regulation treatment, the researchers experimented with mice. The researchers started the experiment by dividing a large sample of mice into two groups. Both groups of mice were injected with melanoma. After the melanoma developed in the mice, the antisense transcripts were identified. The control group did not receive a treatment. However, each mouse in the treatment group was treated with the oligonucleotide application.After the initial treatments, the researchers observed the results. In the control group, the malignant cells remained prevalent. This result was unsurprising. Every subject of the control group died by day 25 of the experiment. The treatment group’s results were shocking. Due to the treatment of oligonucleotide, every member of the treatment group survived until the end of the experiment at day 120.The treatment group was euthanized and examined at the end of day 120. The researchers noted that every mouse that received the down-regulation treatment had no traces of lung or liver metastasis. While the researchers were impressed by these findings, they needed to determine if the results could be extrapolated to other cancers. They received similar results from a renal cell carcinoma model.Down-regulation treatments have not been used in human clinical trials, but the results are promising. The future of oncology is bright.

About Oncotarget

Oncotarget is a free-to-read oncology journal. All papers that are published in the journal are reviewed by a board of editors. The editors are leading researchers at key universities in Europe, North America, and Asia.The founders of Oncotarget believe that information should be free and accessible. They accomplish this mission by using a model that does not rely on paywalls or subscriptions.

How Mikhail Blagosklonny is Helping Advance Useful Anti-Aging Solutions

Mikhail Blagosklonny is among the most recognizable researchers in the world. He is credited with the advancement of breakthrough therapies that have helped alleviate pain and suffering among cancer patients. Recently, he proposed the use of Rapamycin to slow down the aging process. This is a noteworthy announcement considering that Dr. Mikhail Blagosklonny is an authoritative figure in the fields of cancer and aging.

Mikhail has been one of the greatest proponents of Rapamycin, which is a popular cancer treatment medication. According to him, the drug has successfully helped extend the lifespan of cancer patients besides easing the pain and suffering that is associated with the ailment. He believes that basing on this, the drug can also be successfully used to boost the human immune system thus elongating our lifespan. Visit to read more about Mikhail.

Mikhail’s Thesis

According to Dr. Mikhail Blagosklonny, Rapamycin has the ability to slow down aging thus enabling human beings to live longer because it inhibits mTOR, a chemical compound whose production increases with age. In as much as this compound isn’t entirely harmful, it is not important as it is during a human being’s development stage. With time, it promotes the aging process besides causing a host of health complications.

By using Rapamycin, you not only slow down the aging process, but also strengthen your immunity. This goes a long way in delaying the onset of most illnesses that come as a result of aging including cancerous infections. This helps to prolong life. Research similarly indicates that animals that have been treated using Rapamycin tend to live longer than those that are not treated with the drug. This clearly shows that it has the ability to extend human life.

Rapamycin works by inactivating genes that enhance the rate of aging among human beings. In addition, it suppresses cellular senescence, a hormone that greatly contributes to aging. Besides this, the drug helps prevent Parkinson’s disease and Alzeimer, which are associated with aging. In as much as Rapamycin is currently used in cancer treatment only, Mikhail’s research is likely to see it used for a wide range of purposes in coming years. Read more on

Dr. Mikhail Blagosklonny in Brief

Mikhail Blagosklonny has established himself as one of the most passionate cancer researchers. He has made an immense contribution to oncology. For decades, he has also been a priceless asset to the pharmaceutical and medical field. His pioneering studies have helped millions of cancer patients in particular to access affordable cancer treatment.

At the moment, Mikhail works at Roswell Park Cancer Institute, a prominent facility that seeks to unravel cancer therapies. He is an oncology professor at the institution besides leading several research teams. Dr. Blagosklonny previously served as a medical doctor before venturing into the field of oncology. He similarly served on the management board of notable cancer research bodies.

Omar Boraie Supports Important Research

A recent NewsWise article  highlights the crucial work being done at Rutgers University in precision medicine and mentions that an endowed chair was created in the name of supporter Omar Boraie at the Rutgers Cancer Institute to continue doing important research into cancers and their causes. Mr. Boraie, a developer in New Brunswick, ( recently made a generous donation of 1.5 million dollars to help fund the work being done at the Cancer Institute, and the Omar Boraie Chair in Genomic Science will ensure that groud breaking research currently being done at Rutgers will continue.

Boraie has studied chemistry himself and has long been interested in developments in cancer treatments. The director of the cancer institute at Rutgers has praised his generosity.

Specifically, the endowed chair will help fund research in genomics. Researchers at Rutgers are developing ways to create treatments for cancer at the genetic level, allowing them to customize approaches for individual patients. Rutgers is at the very cutting edge of using precision medicine and genomics to treat cancer, and researchers at the university are pioneering ways of attacking extremely rare forms of cancer that do not respond to conventional therapies.

According to the NY Times, the endowed chair has been named to Shridar Ganesan, MD, PhD, one of the leading scientists at the Cancer Institute. The research of Dr. Ganesan extends from the idea that cancer is not a single disease but rather a collection of diseases that require individualized treatments. He has made substantial progress at isolating and defining individual strains of the disease, and this has given hope to both scientists searching for cures and patients suffering from rare cancers.

The Rutgers Cancer Institute works closely with hospitals all over New Jersey to gather data, do research, conduct clinical tests and develop treatments. In short, Omar Boraie’s assistance to its mission has the potential to do a tremendous amount of good.

Read More:

Discover How To Get Alternative Medicine With Proven Results For The Effects Of Chemotherapy

As CEO of Seattle Genetics, Clay Siegall is responsible for pioneering alternative drugs for cancer and other debilitating genetic disorders. He has created several advanced antibodies that have caused his therapeutic practice to become a part of several medical trials. In fact, he is committed to commercializing and patenting his innovative medicine. The goal of Siegall’s medication ideas is to have a positive impact on the lives of people suffering from cancer. His team also has a positive impact on the success of his drug creations and they are committed to their patients and their recovery process. Their goal is to propel their customers into complete remission.


Their main focus at Seattle Genetics is monoclonal antibody therapies that are exclusively for cancer patients. They lead the forefront with antibody-drug conjugates, known as ADC’s in the medical field. They deliver high end cell killing agents that are the center of their research and medical trials. They are committed to individualized personal care for their patients. Seattle Genetics along with Clay Siegall are responsible for many medical breakthroughs. Siegall is well known for counteracting against the effects of chemotherapy. Their primary focus is enhancing antitumor activity associated with cancer. However, Siegall works with a large number of genetic disorders including Hopkins disease and Sickle cell.


The leading drug at Seattle Genetics is ACDETRIC’s in connection with Takeda and Clay Siegall ensures that they have the full commercial rights. This rights are extended to all countries. They will be the foundation of treatment for many genetic disorders including lymphoma, T-cell lymphoma and other serious genetic disorders. Siegall wants to meet the needs of all his patients suffering from cancer and other diseases that are least likely researched. Clay Siegall worked with Glaxo SmithKline for over 16+ years before he came to Seattle Genetics. They were founded in 1988 and focus solely on the improving the lives of patients going through chemotherapy. Siegall has also had many successful internal and preclinical trials devoted to their patients. You’re invited to learn more about Seattle Genetics by visiting their exclusive website today.

Seattle Genetics Medical Innovations under the Leadership Of Clay B. Siegall

Clay Siegall is the current president and chief executive officer of his company, Seattle Genetics, where he also chairs the board. Mr.Clay Siegall graduated from the University of Maryland with a B.S in Zoology and is a Genetics Ph.D. holder from George Washington University.

Siegall has previously worked for Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997, the National Cancer Institute, the National Institute of Health between 1988 and 1991.
He is also a board member of Mima Therapeutica Washington Roundtable, Alder Biopharmaceuticals, and Ultragenyx Pharmaceuticals.

Clay B. Siegall co-partnered to launch Seattle Genetics in 1998.The scientists set up the firm with an aim to offer cancer patients with treatment therapies, conduct further research on the cancer illness and develop drugs that treat the afflicted people through innovative research methodologies.

Under Clay’s guidance, Seattle Genetics has developed ADCs, which are antibody drug conjugates and earned the 2011 FDA verification for its first ADC production, brentuximab vedotin (ADCETRIS).ADCETRIS is an international drug legal in over 60 nations with the collaboration of Seattle Genetics and Takeda Pharmaceutical Company. Seattle continues to develop more effective cancer treatment drugs as the ADCs.

Seattle Genetics has acquired several licenses for its ADC innovations such as with GlaxoSmithKline, Abbvie, Genentech (Roche) and Pitzer. These relationships have returned more than $325 million. Clinical developments have reported more than 20 ADCs in the process with the Seattle Genetics technology in both internal and collaborator programs.
The firm has raised over $1.2 billion in private and public funding in addition to the federal contribution in 2001.

Clay Siegall has documented his long-standing knowledge in specialization in over 70 publications and had 15 patents. Clay has earned the 2013 Alumnus of the year for Mathematics, Computer and Natural Sciences Award by Maryland University and the Pacific Northwest Ernst &Young Entrepreneur award in 2012.

Clay B. Siegall revealed his plans in the Seattle Genetics prospects in drug development in an interview which was a publication in BizJournals.
He intends to expand the employee capacity of his firm by 100 annually to increase the workforce and efficiency of drug development.
Clay has also sat with Jim Cramer of CNBC news to discuss the stock business of his company which is a haven for investors.

Seattle Genetics Is Moving To Create More Drugs

Clay Siegall started Seattle Genetics with a vision to create cancer drugs that were based on the antibody therapy that he created himself. This was part of his much larger vision that he had for the company where he could reach people across the country, and he has now taken the company so far that it has to expand to more drugs. They are getting so big that they cannot keep up with their expansion, and they are working on sales that are nearly $100 million in a year. They are funded very well, and they have a stock price that is remaining very steady.

Creating new drugs is a passion for Clay Siegall, and he wants to be sure that he has reached as many people as he can find. Up to 12 new drugs will be created at his company, and all of the 12 new drugs will cover a type of cancer that has not been covered up this point. That in and of itself is very important, and it is something that people will be able to participate in on a new level. It is something that people have to look into, and they should ask their doctors how they can be a part of the trials.

The trials have produced sales and results that people can be happy with, and now it has become time for them to come up to 12 drugs. All these new cancer drugs will change the lives of people who can get in treatment and see a change. They will have new options because their cancers might not have been treated before, but now there is a way to make these things go away. Clay Siegall thinks that he can help people who might not have had a good prognosis, and he knows that he can do it with his antibody therapy.

Learn more about Cay Siegall:

Seattle Genetics, with Clay Siegall at the helm, blazing the Trail in Cancer Research

Seattle Genetics Co-Founder, Clay Siegall, Ph.D., has been appointed to the Board of Directors for Mirna Therapeutics as an outside director. Founded in 2007 and based in Austin, Texas, Mirna Therapeutics’ main focus is cancer research, an area Clay Siegall has an extensive background in. The experience that Dr. Siegall has will help to guide microRNA therapeutics toward developmental advancements. Dr. Siegall is also on the Board of Directors for Alder BioPharmaceuticals.

Read the original article:

Seattle Genetics Co-Founder Appointed to Board of Directors for Mirna Therapeutics Inc.

Clay Siegall, a graduate of the University of Maryland, where he received a Bachelor of Science in Zoology and a graduate of George Washington University, where he received his Ph.D. in genetics, helped Co-Found Seattle Genetics in 1988. He is the current President, Chief Executive Officer, and Chairman of the Board of Directors. Seattle Genetics has been successful in creating anti-body based therapies for cancer patients. Dr. Siegall also has over 70 published works and hold 15 patents.

Prior to co-founding Seattle Genetics, Dr. Siegall worked for Bristol-Myers Squibb Pharmaceutical Research Institute followed then by the National Cancer Institute. The experience that Dr. Siegall bought with him has helped Seattle Genetics to develop an extensive list of clinical and preclinical product candidates that target cancer and autoimmune indications. Seattle Genetics has also been a leader in antibody technologies, most notably an anti-body drug conjugate, also known as ADC.

Seattle Genetics’ first introduction into ADCs was with ADCETRIS, an anti-body drug conjugate that has been used to treat 15,000 lymphoma patients globally to-date. Seattle Genetics is also advancing seven clinical-stage programs, focusing on myeloid leukemia and non-Hodgkin lymphoma. In collaborating with a dozen leading biotechnology and pharmaceutical companies, more than 20 of the ADCs are in clinical development through proprietary and collaborator programs.

With Dr. Clay Siegall paving the way, Seattle Genetics is advancing breakthrough therapies for cancer by focusing on developing innovative treatment of cancer. Being an industry leader in ADCs, targeting the antibodies ability to deliver cell-killing agents, Seattle Genetics is trailblazing the way for deep product pipelines to address significant unmet medical needs of patients that may not have been able to get those needs met previously.

Read about Clay: